Novo Nordisk IT unit set to announce IPO; Alexion weighs new European HQ in Zurich;

@FiercePharma: Our newest special report is live! The top 10 most expensive drugs of 2013. Feature | Follow @FiercePharma

@EricPFierce: Novartis says construction delay of Russian plant no big deal, technical changes and not tied to sanctions. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Sanofi wins kudos for airing bribery probe. Phase II? Take to social media. Article | Follow @CarlyHFierce

> Novo Nordisk ($NVO) is on the brink of announcing an initial public offering for its information technology unit, NNIT, a Danish newspaper reports; the drugmaker said in January that it was considering an NNIT spinoff. Report

> U.S.-based Alexion Pharmaceuticals ($ALXN) says it's weighing a move of its European headquarters to Zurich, as part of a plan to expand operations in the country. Report

> The Belgian biotech Galapagos wooed its new chief financial officer, Bart Filius, away from his post as VP of Sanofi Europe. Report

> AstraZeneca's ($AZN) new head of investor relations says he's looking to set up an IR beachfront in the U.S. Report

> Retrophin ($RTRX) agreed to sell off some "non-core" assets, including the oxytocin nasal spray Syntocinon, to Turing Pharmaceuticals for $3 million, plus debt assumption. Release

Medical Device News

@FierceMedDev: Who are today's leading women in med tech? Check out our top women in medical devices list to find out. Special report | Follow @FierceMedDev

@VarunSaxena2: Invitae raises $120M to offer cheap, easy genetic analysis. Story | Follow @VarunSaxena2

@EmilyWFierce: $COV recalled some defibrillator electrodes made by $PHG. Story from MassDevice | Follow @EmilyWFierce

@MichaelGFierce: Stem cell-derived beta cells deliver insulin in response to blood sugar levels. Story | Follow @MichaelGFierce

> In latest M&A news, ConvaTec is up for sale. Story

> St. Jude posts modest gains in Q3 financials led by new products. Article

> Beyond glucose: Developing a diagnostic test for fructose intolerance. More

Biotech News

@FierceBiotech: Meet some of the revolutionaries in biotech R&D. Report | Follow @FierceBiotech

@JohnCFierce: AbbVie to Shire: Maybe we should reconsider that $54B merger deal after all - $SHPG down 27%. Article | Follow @JohnCFierce

@DamianFierce: Fantastically timed press release: "Shire Announces the Organize Your Stuff Contest Winners." Release | Follow @DamianFierce

@EmilyMFierce: These 10 drugs could stop Ebola. Feature | Follow @EmilyMFierce

> Selecta banks $20M for trial work, inks a pact with Sanofi on diabetes. Story

> Forward Pharma pulls off a $221M IPO with eyes on unseating Biogen. More

> DNAtrix pockets $20M to get its cancer-fighting virus into Phase III. Article

Drug Delivery News

> Robert Langer talks science, business and how they intersect. More

> Stem cell-derived beta cells deliver insulin in response to blood sugar levels. Story

> Stealthy, DNA-based 'nano-cocoons' deliver cancer-killing payloads. Report

> Alnylam releases data on its Phase II study of TTR-mediated amyloidosis patients. Item

> Intersect ENT says latest data on dissolving implants for chronic sinusitis are encouraging. Article

Diagnostics News

> Gene sequencing helps Northwestern team diagnose one cause of epilepsy. More

> Exact Sciences nails coveted Medicare coverage for colon cancer DNA test. News

> SomaLogic, CO hospital to develop biomarkers/Dx tests for childhood diseases. Story

> British startup finishes quick and easy Ebola test. Report

> Biocept, Rosetta Genomics want to beef up Dx and biomarker-detection power. Article

Pharma Marketing News

> Teva's SCOTUS appeal is here. But how much can the outcome really affect Copaxone's market share? More

> World's best CEOs? Gilead, Allergan, Novo and Valeant make top 10. Read

> Looking 'beyond the pill'? Start with an app--and then follow this to-do list. Story

> Can Amgen's marketing muscle vault its Humira biosim ahead of rivals? More

> Pictures tell the story in AstraZeneca's breast cancer photo-sharing push. Article

And Finally... How a cooling cap could change breast cancer treatment. Report

Suggested Articles

Dupixent's number-one position in the eczema market will be tough to maintain as two dozen rivals line up to unseat it, Cantor Fitzgerald warns.

Just months after a C-suite shakeup at Amneal, the generics company has struck a $220 million deal for AvKare, known on the street as R&S Northeast. 

The FTC has sent Elanco a "second request" for details of the acquisition, signaling antitrust concerns about the $7.6 billion deal.